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Abstract
Background Studies of asthma and chronic obstructive pulmonary disease (COPD) typically focus on these
diagnoses separately, limiting understanding of disease mechanisms and treatment options. NOVELTY is a
global, 3-year, prospective observational study of patients with asthma and/or COPD from real-world
clinical practice. We investigated heterogeneity and overlap by diagnosis and severity in this cohort.
Methods Patients with physician-assigned asthma, COPD or both (asthma+COPD) were enrolled, and
stratified by diagnosis and severity. Baseline characteristics were reported descriptively by physician-
assigned diagnosis and/or severity. Factors associated with physician-assessed severity were evaluated
using ordinal logistic regression analysis.
Results Of 11243 patients, 5940 (52.8%) had physician-assigned asthma, 1396 (12.4%) had asthma
+COPD and 3907 (34.8%) had COPD; almost half were from primary care. Symptoms, health-related
quality of life and spirometry showed substantial heterogeneity and overlap between asthma, asthma
+COPD and COPD, with 23%, 62% and 64% of patients, respectively, having a ratio of post-
bronchodilator forced expiratory volume in 1 s to forced vital capacity below the lower limit of normal.
Symptoms and exacerbations increased with greater physician-assessed severity and were higher in
asthma+COPD. However, 24.3% with mild asthma and 20.4% with mild COPD had experienced ⩾1
exacerbation in the past 12 months. Medication records suggested both under-treatment and over-treatment
relative to severity. Blood eosinophil counts varied little across diagnosis and severity groups, but blood
neutrophil counts increased with severity across all diagnoses.
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Conclusion This analysis demonstrates marked heterogeneity within, and overlap between, physician-
assigned diagnosis and severity groups in patients with asthma and/or COPD. Current diagnostic and
severity classifications in clinical practice poorly differentiate between clinical phenotypes that may have
specific risks and treatment implications.
Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are among the most common
non-communicable diseases worldwide, contributing a significant burden to patients and healthcare
systems [1]. There is increasing recognition that there are numerous phenotypes of asthma and COPD, and
that conventional diagnostic criteria for the two diseases overlap [2, 3]. Despite this, most mechanistic
studies and regulatory clinical trials are limited to either asthma or COPD based on conventional diagnostic
criteria, and may exclude up to 90% of real-world patients [4, 5]. This has hampered progress in
understanding the pathobiology of obstructive lung disease and its relevance to patients in clinical practice.
Observational studies and pragmatic trials with broader eligibility criteria are needed to complement the
randomised controlled trial evidence base [6].
To support the development of personalised management and improve clinical outcomes, the 2018 Asthma
Lancet Commission [7] called for new ways of classifying asthma and COPD based on clinical or
inflammatory characteristics (phenotypes) and underlying mechanisms. Advances in developing effective
treatments require identification of precise molecular mechanisms or distinct treatment responses that can
be linked to well-defined patient subgroups (i.e. endotypes) [8].
Although important insights have been obtained from studying selected or geographically limited
populations with a single diagnostic label (“asthma” or “COPD”) based on conventional diagnostic criteria
[9–11], there have been few prospective studies in real-world clinical practice that have included patients
with asthma and/or COPD.
The NOVEL observational longiTudinal studY (NOVELTY) [12] is a global, 3-year, prospective
observational study across the full spectrum of asthma and/or COPD (www.clinicaltrials.gov,
NCT02760329). The primary objectives of NOVELTY are to describe patient characteristics, treatment
patterns and disease burden over time, and to identify clinical phenotypes and molecular endotypes
associated with differential outcomes in patients with a diagnosis or suspected diagnosis of asthma and/or
COPD [12]. NOVELTY is systematically collecting real-world data from specialist centres and primary
care, including many patients who would usually be excluded from studies in “pure” asthma or COPD.
Here, we investigate heterogeneity among, and overlap between, groups identified by physician-assigned
diagnosis and severity labels among patients being treated for asthma and/or COPD in the community, and




The NOVELTY study design has been published previously [12] and details can also be found on the
study website (noveltystudy.com). Briefly, patients aged ⩾18 years with a physician-assigned diagnosis or
suspected (i.e. not confirmed) diagnosis of asthma, COPD or both (asthma+COPD) were enrolled by
primary care physicians, pulmonologists or allergists from active clinical practices in 19 countries in the
Americas, Asia, Australia and Europe; 11 countries also recruited patients ⩾12–<18 years of age
(supplementary table S1). Patients were excluded only if their primary respiratory diagnosis was not
asthma or COPD, they had participated in a respiratory interventional trial during the previous 12 months
or they were considered unlikely to complete 3 years of follow-up. To ensure sufficient numbers for
regional or subgroup analyses, sampling was stratified by diagnosis (asthma, asthma+COPD, COPD) and
by physician-assessed severity (mild, moderate, severe); enrolment was capped in some subgroups in some
countries when target numbers were reached. No diagnostic or severity criteria were provided.
The study was approved in each participating country by the relevant institutional review boards and all
patients provided written informed consent.
Measurements
As detailed elsewhere [12], physicians recorded baseline demographics; smoking status; disease history
(years since diagnosis, age of onset); respiratory and non-respiratory comorbidities; diagnosis of
emphysema; allergies (including whether confirmed by allergy testing); medications; fractional exhaled
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nitric oxide (FENO) level (supplementary material); and pre- and post-bronchodilator forced expiratory
volume in 1 s (FEV1), bronchodilator responsiveness (reversibility), forced vital capacity (FVC), FEV1/
FVC and forced expiratory flow at 25–75% of FVC (FEF25–75%), with predicted and lower limit of normal
(LLN) values based on Global Lung Function Initiative multi-ethnic reference equations [13]. Physicians
were asked to record exacerbations as: “During the past 12 months, on how many occasions has your
patient experienced an exacerbation of their asthma or COPD beyond the patient’s usual day-to-day
variance?” [14]. For bronchodilator responsiveness testing, patients were required to have withheld
short-acting bronchodilators for ⩾6 h and long-acting bronchodilators for 12–24 h, as appropriate. Baseline
data for selected patient-reported outcomes (PROs) that are “diagnosis-agnostic” (i.e. not specific to asthma
or COPD) for evaluating symptoms (modified Medical Research Council (mMRC) dyspnoea grade) [15]
and health-related quality of life (HRQoL) or health status (St George’s Respiratory Questionnaire (SGRQ)
total score [16] and Chronic Airways Assessment Test (CAAT) score) are also reported. The CAAT
(© 2009 GlaxoSmithKline; all rights reserved) is a modified (with permission) version of the COPD
Assessment Test [17], with the term “COPD” replaced with “chronic airways” and “pulmonary disease” in
the questionnaire title and instruction, respectively [12]. Physicians did not have access to PRO scores
when assessing asthma and COPD severity. Blood was collected from consenting patients for cell counts.
Statistical analysis
Results are presented as descriptive statistics, stratified by physician-assigned diagnosis/suspected diagnosis
(combined), physician-assessed severity (mild, moderate, severe/very severe (pooled)), recruitment setting
(primary care or non-primary care) and/or diagnosis or suspected diagnosis. Medications were analysed by
class (supplementary table S2). Data for patients from China were excluded from the present analyses
owing to a change in regulations about data transfer in May 2019.
Factors independently associated with physician-assessed severity were evaluated using ordinal logistic
regression analysis, treating severity categorisation as an ordinal variable. The variables included in the
ordinal models were selected using stepwise regression, starting with a non-redundant set of variables
(supplementary material). Ordinal regression models were fitted for asthma-only patients and COPD-only
patients separately, and overall. Proportional odds ratios and 95% confidence intervals are reported. All
analyses were performed using R version 5.1.2 (R Foundation for Statistical Computing).
Results
Analysis population
This analysis includes all patients from 18 countries (excluding China) who met the inclusion criteria and
had data for diagnosis as of March 5, 2018 (N=11243; supplementary table S1).
Patients were enrolled from primary care (46.7%), university hospitals (26.7%), specialist research facilities
(11.8%), non-university hospitals (8.7%), specialist clinics (4.4%) and unknown settings (0.9%). Patients
recruited from primary care had milder asthma and were less likely to have a diagnosis of emphysema or
to have had allergy testing or post-bronchodilator spirometry performed than those recruited from other
settings (supplementary table S3).
Heterogeneity and overlap by physician-assigned diagnosis
At baseline, 5940 patients (52.8%) had a physician-assigned diagnosis of asthma only, 1396 (12.4%)
asthma+COPD and 3907 (34.8%) COPD only (table 1); the diagnosis was recorded as suspected for 4.3%
(supplementary table S4). Overall, 52.3% were female (asthma 62.5%, COPD 38.5%). Patients with
asthma were younger than those with asthma+COPD or COPD.
On average, patients with asthma had been diagnosed earlier than those with asthma+COPD or COPD
(table 1). Respiratory symptoms reportedly commenced before 12 years of age for 25.0% and 21.0% of
asthma and asthma+COPD patients, respectively, but also for 4.5% of COPD patients (table 1). Among
patients with asthma+COPD, the first diagnosis was asthma for 56.5%, COPD for 12.8% and the
remainder (30.7%) were diagnosed simultaneously. Among patients diagnosed in the last 5 years,
physicians did not list spirometry as a diagnostic criterion for 35.3%, 13.8% and 26.4% of patients with
asthma, asthma+COPD and COPD, respectively (supplementary figure S1).
Patients with asthma+COPD or COPD were more likely to be current or former smokers than those with
asthma; however, 6.3% of patients with COPD had never smoked, and 38.1% of patients with asthma were
current or former smokers (table 1).
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Upper airway comorbidities (allergic rhinitis, recurrent/chronic non-allergic rhinitis/sinusitis and nasal or
sinus polyps) were more prevalent among patients with asthma or asthma+COPD than with COPD,
whereas cardiovascular comorbidities were more prevalent among patients with asthma+COPD or COPD
than with asthma (figure 1).
Blood eosinophil count was similar across physician-assigned diagnoses; eosinophil percentage of total
leukocytes was lower among those with COPD, but there was substantial overlap. Blood neutrophil counts
were higher among those with asthma+COPD and COPD, and median FENO was lower among never- or
former smokers with COPD than those with asthma (supplementary table S5).
Heterogeneity and overlap by physician-assigned diagnosis and severity
Demographics and disease history
There were no consistent differences in demographics across diagnosis/severity groups (table 2).
Approximately one third of patients were obese (body mass index ⩾30.0 kg·m−2); obesity was less
common among patients with severe COPD than with severe asthma/asthma+COPD. Current smoking was
less common in patients with severe COPD than with mild or moderate COPD. Diagnosis of emphysema
increased by increasing severity in asthma+COPD and COPD but was also reported in mild asthma (table 2).
TABLE 1 Demographics and disease history of the NOVELTY population, by physician-assigned diagnosis
Asthma Asthma+COPD COPD Total
Subjects N# 5940 1396 3907 11243
Female sex 3714 (62.5) 655 (46.9) 1506 (38.5) 5875 (52.3)
Age years 52.0±17.1 64.7±10.3 66.6±9.6 58.7±15.8
Ethnicity
N with data 5925 1396 3907 11228
Caucasian 4193 (70.8) 1065 (76.3) 3144 (80.5) 8402 (74.8)
African American 271 (4.6) 57 (4.1) 268 (6.9) 596 (5.3)
North East Asian¶ 911 (15.4) 200 (14.3) 269 (6.9) 1380 (12.3)
South East Asian 109 (1.8) 24 (1.7) 36 (0.9) 169 (1.5)
Other 441 (7.4) 50 (3.6) 190 (4.9) 681 (6.1)
Smoking status
N with data 5917 1390 3894 11201
Never smoked 3652 (61.7) 167 (12.0) 246 (6.3) 4065 (36.3)
Former smoker 1787 (30.2) 882 (63.5) 2495 (64.1) 5164 (46.1)
Current smoker 478 (8.1) 341 (24.5) 1153 (29.6) 1972 (17.6)
Age at diagnosis
Asthma 33.4±21.4 42.6±23.0 NA 35.2±22.0
COPD NA 57.2±11.7 58.8±11.9 58.4±11.9
Asthma or COPD 33.4±21.4 42.2±22.4 58.8±11.9 43.4±22.1
Onset of respiratory symptoms at age <12 years 1487 (25.0) 293 (21.0) 176 (4.5) 1956 (17.4)
Family history
Asthma 2330 (39.2) 541 (38.8) 647 (16.6) 3518 (31.3)
COPD 722 (12.2) 376 (26.9) 937 (24.0) 2035 (18.1)
Allergies 2153 (36.2) 370 (26.5) 475 (12.2) 2998 (26.7)
Physician-assessed severity+
N with data 5935 1392 3905 11232
Mild 2175 (36.6) 243 (17.5) 1125 (28.8) 3543 (31.5)
Moderate 2108 (35.6) 626 (45.0) 1206 (30.9) 3940 (35.1)
Severe 1652 (27.8) 523 (37.6) 1574 (40.3) 3749 (33.4)
Data are presented as n (%) or mean±SD, unless otherwise stated. For percentages, the denominator is given
when different from the total number of patients (N with data, excluding “unknown”). COPD: chronic
obstructive pulmonary disease; NA: not applicable. #: >90% of patients had complete data for variables;
¶: including Japanese patients; +: recruitment was stratified by diagnosis/severity with the aim of achieving
similar numbers of patients in each group; for patients with asthma+COPD, the severity category was the worse
of the two physician-assessed severity classifications, and patients with COPD classified as “very severe” were
included in the “severe” group. Given the large sample size, any minor differences among categories may be
expected to yield a statistically significant result, so for the sake of brevity, p-values for heterogeneity are
not provided.
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Symptoms, health status and comorbidities
Across the three diagnosis groups, mMRC dyspnoea grade, SGRQ total score and CAAT score were worse
with greater physician-assessed severity (figure 2), but there was marked variation within, and overlap
between, each diagnosis (supplementary figure S2, supplementary table S5) and diagnosis/severity group
(figure 2, supplementary figure S3, supplementary table S6). Within each severity category, patients with
asthma+COPD or COPD were more likely to have clinically important dyspnoea (mMRC grade ⩾2),
worse HRQoL and worse overall health status than those with asthma (figure 2, supplementary figure S3).
Only 38.1% of patients with severe asthma and 24.3% with severe COPD reported their health to be very
good/good, and 14.4% and 24.1%, respectively, described their health as poor/very poor (table 2).
Nasal or sinus polyps were reported across all diagnosis/severity groups but were most common in severe
asthma (table 2). Cardiovascular comorbidities were more common with greater severity across the total
population (supplementary table S6).
Exacerbations
The proportions of patients with ⩾1 or ⩾2 exacerbations in the past 12 months increased across severity
groups, but notably included 24.3% and 7.3% of patients with mild asthma and 20.4% and 5.3% of
patients with mild COPD, respectively (table 2). Conversely, of patients with severe asthma or severe
COPD, 48.3% and 50.6%, respectively, were not reported to have had an exacerbation in the previous
12 months (figure 3). Hospital admissions for exacerbations in the past 12 months also increased across
severity groups (table 2).
Spirometric characteristics
Marked heterogeneity was seen in lung function across diagnosis and severity groups, particularly in




























































































FIGURE 1 a) Respiratory and b) non-respiratory comorbidities in the NOVELTY population, by physician-assigned diagnosis. COPD: chronic
obstructive pulmonary disease; CAD: coronary artery disease; MI: myocardial infarction. #: from an electronic case report form entry under
“Respiratory Comorbidities” and/or from a record of abnormal computed tomography findings; ¶: any cardiovascular disease other than
hypertension, CAD, MI or congestive heart failure.
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Physician-assigned diagnosis and severity
mMRC Grade 4 mMRC Grade 1
mMRC Grade 3 mMRC Grade 0
mMRC Grade 2
mMRC Grade 4 mMRC Grade 1
mMRC Grade 3 mMRC Grade 0
mMRC Grade 2
mMRC Grade 4 mMRC Grade 1
mMRC Grade 3 mMRC Grade 0
mMRC Grade 2
FIGURE 2 Variability in a) modified Medical Research Council (mMRC) dyspnoea grade (available for 96.5% of
patients), b) St George’s Respiratory Questionnaire (SGRQ) total score (available for 69.3% of patients) and
c) Chronic Airways Assessment Test (CAAT#) total score (available for 70.0% of patients) by physician-assigned
diagnosis and severity.¶ For b and c, boxes represent the median (interquartile range (Q1–Q3); whiskers extend
to 1.5 times the interquartile range, with circles representing individual outliers. COPD: chronic obstructive
pulmonary disease. #: the CAAT is a trademark of the GlaxoSmithKline group of companies. © 2009
GlaxoSmithKline. All rights reserved. It has been modified from the COPD Assessment Test, with permission, by
replacement of the term “COPD” with “chronic airways” and “pulmonary disease” in the questionnaire title and
instruction, respectively. ¶: recruitment was stratified by diagnosis/severity with the aim of achieving similar
numbers of patients in each group; for patients with asthma+COPD, the severity category is the worse of the
two physician-assessed severity classifications, and patients with COPD classified as “very severe” were
included in the “severe” group.
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TABLE 2 Clinical characteristics of the NOVELTY population, by physician-assigned diagnosis and severity#
Physician-assigned asthma Physician-assigned asthma+COPD Physician-assigned COPD
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe
Subjects N¶ 2175 2108 1652 243 626 523 1125 1206 1574
Female sex 1375 (63.2) 1297 (61.5) 1039 (62.9) 120 (49.4) 293 (46.8) 240 (45.9) 448 (39.8) 481 (39.9) 575 (36.5)
Age years 50.0±17.7 53.2±17.0 53.1±16.2 64.0±10.2 65.6±10.1 64.0±10.6 65.1±10.5 66.6±9.6 67.8±8.8
BMI kg·m−2 27.7±6.5 28.1±6.8 28.7±7.0 29.0±6.6 28.6±6.9 28.6±6.4 28.2±6.0 28.3±6.9 26.8±6.3
N with data 2041 1925 1533 235 595 494 1073 1120 1469
<18.5 50 (2.4) 49 (2.5) 49 (3.2) 7 (3.0) 14 (2.4) 11 (2.2) 28 (2.6) 34 (3.0) 105 (7.1)
18.5–<25.0 734 (36.0) 667 (34.6) 431 (28.1) 55 (23.4) 175 (29.4) 139 (28.1) 299 (27.9) 346 (30.9) 531 (36.1)
25.0–<30.0 655 (32.1) 605 (31.4) 511 (33.3) 88 (37.4) 201 (33.8) 166 (33.6) 391 (36.4) 371 (33.1) 451 (30.7)
⩾30.0 602 (29.5) 604 (31.4) 542 (35.4) 85 (36.2) 205 (34.5) 178 (36.0) 355 (33.1) 369 (32.9) 382 (26.0)
Smoking status
N with data 2170 2101 1644 243 622 521 1118 1204 1572
Never smoked 1364 (62.9) 1245 (59.3) 1042 (63.4) 23 (9.5) 73 (11.7) 71 (13.6) 82 (7.3) 66 (5.5) 98 (6.2)
Former smoker 619 (28.5) 671 (31.9) 496 (30.2) 156 (64.2) 391 (62.9) 333 (63.9) 620 (55.5) 764 (63.5) 1111 (70.7)
Current smoker 187 (8.6) 185 (8.8) 106 (6.4) 64 (26.3) 158 (25.4) 117 (22.5) 416 (37.2) 374 (31.1) 363 (23.1)
Diagnosis of emphysema 44 (2.0) 42 (2.0) 51 (3.1) 50 (20.6) 176 (28.1) 208 (39.8) 269 (23.9) 438 (36.3) 840 (53.4)
⩾1 allergy reported 1383 (63.6) 1340 (63.6) 1076 (65.1) 126 (51.9) 290 (46.3) 299 (57.2) 297 (26.4) 302 (25.0) 315 (20.0)
Allergy testing performed 727 (33.4) 703 (33.3) 753 (45.6) 51 (21.0) 150 (24.0) 153 (29.1) 94 (8.4) 77 (6.4) 109 (6.9)
Atopic+ 605 (83.2) 558 (79.4) 623 (82.7) 39 (76.5) 97 (64.7) 126 (82.4) 49 (52.1) 46 (59.7) 66 (60.6)
Nasal or sinus polyps 67 (3.1) 87 (4.1) 139 (8.4) 5 (2.1) 23 (3.7) 11 (2.1) 4 (0.4) 4 (0.3) 9 (0.6)
Overall health status§
N with non-missing data 1461 1442 1182 162 434 376 747 820 1121
Very good 226 (15.5) 156 (10.8) 69 (5.8) 13 (8.0) 21 (4.8) 9 (2.4) 67 (9.0) 49 (6.0) 28 (2.5)
Good 665 (45.5) 641 (44.5) 381 (32.2) 69 (42.6) 136 (31.3) 98 (26.1) 276 (36.9) 256 (31.2) 244 (21.8)
Fair 485 (33.2) 522 (36.2) 562 (47.5) 65 (40.1) 217 (50.0) 167 (44.4) 336 (45.0) 382 (46.6) 579 (51.7)
Poor 78 (5.3) 110 (7.6) 142 (12.0) 13 (8.0) 55 (12.7) 79 (21.0) 57 (7.6) 118 (14.4) 224 (20.0)
Very poor 7 (0.5) 13 (0.9) 28 (2.4) 2 (1.2) 5 (1.2) 23 (6.1) 11 (1.5) 15 (1.8) 46 (4.1)
Post-bronchodilator FEV1
% predictedƒ




0.78±0.09 0.75±0.11 0.69±0.14 0.67±0.12 0.62±0.13 0.53±0.16 0.68±0.11 0.60±0.13 0.46±0.14
N with data (for <0.7) 1797 1727 1413 204 534 446 956 993 1336
<0.7 288 (16.0) 471 (27.3) 637 (45.1) 113 (55.4) 386 (72.3) 371 (83.2) 514 (53.8) 716 (72.1) 1233 (92.3)
N with data (for LLN) 1755 1685 1380 201 516 430 941 962 1297
<LLN 203 (11.6) 366 (21.7) 549 (39.8) 83 (41.3) 302 (58.5) 324 (75.3) 340 (36.1) 576 (59.9) 1130 (87.1)
Bronchodilator
responsiveness %
5.4±8.4 5.9±9.0 8.3±11.0 6.3±8.6 7.3±9.7 10.1±13.5 4.8±10.0 5.7±11.1 8.4±12.5
N with data 1724 1672 1379 196 513 426 921 931 1267
>12% and >200 mL 214 (12.4) 237 (14.2) 308 (22.3) 29 (14.8) 91 (17.7) 97 (22.8) 109 (11.8) 129 (13.9) 171 (13.5)
Exacerbations in the past
12 months##
0.4±1.1 0.5±1.2 1.2±2.0 0.5±0.9 0.9±1.7 1.4±2.1 0.3±0.7 0.5±0.9 1.0±1.6
N with data 2166 2089 1635 242 624 522 1112 1193 1565
⩾1 527 (24.3) 642 (30.7) 798 (50.9) 84 (34.7) 258 (41.3) 310 (59.4) 227 (20.4) 354 (29.7) 796 (50.9)
⩾2 158 (7.3) 240 (11.5) 434 (26.5) 32 (13.2) 121 (19.4) 158 (30.3) 59 (5.3) 113 (9.5) 342 (21.9)
Healthcare utilisation





27 (1.2) 47 (2.2) 147 (8.9) 8 (3.3) 47 (7.5) 70 (13.4) 33 (3.0) 85 (7.1) 284 (18.1)
Data are presented as n (%) or mean±SD, unless otherwise stated. For percentages, the denominator is given when different from the total number
of patients (N with data, excluding “unknown”). COPD: chronic obstructive pulmonary disease; BMI: body mass index; FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; LLN: lower limit of normal. #: recruitment was stratified by diagnosis/severity with the aim of achieving
similar numbers of patients in each group; for patients with asthma+COPD, the severity category is the worse of the two physician-assigned severity
classifications, and patients with COPD classified as “very severe” were included in the “severe” group; ¶: ∼80% of patients had post-bronchodilator
spirometry data, 70% had patient-reported outcome data and >90% had complete data for other variables; +: data presented as n (% of those with
allergy testing); §: data presented as n (% of patients with non-missing data), from the question that precedes the St George’s Respiratory
Questionnaire: “please tick in one box to show how you describe your current health”; ƒ: Global Lung Function Initiative multi-ethnic reference
equations were used to calculate % predicted values [13]; ##: includes mild, moderate and severe exacerbations from the following question in the
electronic case report form: “During the past 12 months, on how many occasions has your patient experienced an exacerbation of their asthma or
COPD beyond the patient’s usual day-to-day variance?”
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lower with greater physician-assessed severity, but reduced post-bronchodilator FEV1/FVC and FEV1 were
prevalent across all severity groups, particularly in asthma+COPD and COPD (table 2, figure 4,
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FIGURE 3 Frequency distribution by a) the number of exacerbations# and b) the mean number of
exacerbations (among all patients, including those with no exacerbations) in the past 12 months, by
physician-assigned diagnosis and severity.¶ In b, data are presented as mean+SD. COPD: chronic obstructive
pulmonary disease. #: exacerbations include mild, moderate and severe exacerbations, from the following
question in the electronic case report form: “During the past 12 months, on how many occasions has your
patient experienced an exacerbation of their asthma or COPD beyond the patient’s usual day-to-day variance?”;
¶: recruitment was stratified by diagnosis/severity with the aim of achieving similar numbers of patients in each
group; for patients with asthma+COPD, severity was based on the more severe of the physician’s assessed
severity for asthma and for COPD, and patients with COPD classified as “very severe” were included in the
“severe” group.
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FIGURE 4 Heterogeneity in a–i) post-bronchodilator forced expiratory volume in 1 s (FEV1), j–r) post-bronchodilator FEV1/forced vital capacity (FVC)
and s–aa) bronchodilator responsiveness, by physician-assigned diagnosis and severity. For continuous data, density is calculated as frequency
divided by category width. The solid black lines show the median values. Grey shading shows the spirometric thresholds used in asthma/chronic
obstructive pulmonary disease (COPD) diagnostic criteria [2, 3]. See supplementary table S3 for the number of patients with post-bronchodilator
spirometry data. Global Lung Function Initiative multi-ethnic reference equations were used to calculate % predicted values [13].
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Among patients with a diagnosis of COPD, only 63.9% had persistent airflow limitation, defined as
post-bronchodilator FEV1/FVC <LLN (or 75.0% with FEV1/FVC <0.7), with similar findings for
asthma+COPD (supplementary table S5). Among patients with asthma, 23.2% (<LLN) and 28.3% (<0.7)
had persistent airflow limitation (supplementary table S5).
The distribution of bronchodilator responsiveness (available for 80.3% of patients (n=9034)) overlapped
across physician-assigned diagnosis and severity groups (supplementary figures S2 and S3), and 13.1% of
patients with COPD had bronchodilator responsiveness of >12% and >200 mL at the baseline visit,
compared with 19.1% with asthma+COPD and 15.9% of patients with asthma (supplementary table S5).
Among patients with asthma or asthma+COPD, bronchodilator responsiveness increased with increasing
physician-assessed severity (table 2, supplementary figure S3).
Medications
Overall, intensity of therapy increased with increasing physician-assessed severity across diagnosis groups,
although marked heterogeneity was observed within diagnosis and severity groups (table 3). Patients
classified as having mild asthma were most commonly receiving medium/high-dose inhaled corticosteroid
(ICS) long-acting β2-agonists (LABA) (25.6%), low-dose ICS-LABA (22.5%) or short-acting bronchodilators
without ICS (16.0%), but 2.1% were receiving maintenance oral corticosteroids (OCS). Among those with
severe asthma, 39.3% were receiving leukotriene modifiers, 30.3% biologic therapy and 13.4% maintenance
OCS. Patients with mild COPD were commonly taking short-acting bronchodilators (29.9%) or LABAs and/
or long-acting muscarinic antagonists (LAMA) (41.8%) without ICS, but this was also the treatment for
17.0% and 25.1%, respectively, of patients with severe COPD. The most common treatment among patients
with severe COPD was triple therapy (ICS+LABA+LAMA) (49.5%). Triple therapy was also being taken by
16.6% of patients with severe asthma and 50.1% with severe asthma+COPD, but also by 23.7% with mild
asthma+COPD. Overall, 10.9%, 15.9% and 44.0% of patients with asthma, asthma+COPD and COPD,
respectively, were not taking any ICS-containing therapy (supplementary table S6).
Biomarkers
There was little variation in blood eosinophil counts by severity, even after excluding patients taking
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FIGURE 4 Continued.
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physician-assessed severity across all diagnoses; there were no clear patterns for eosinophil and neutrophil
percentages by severity (table 3). Levels of FENO among non-smokers were similar across diagnosis/
severity groups, except for lower levels in patients with severe COPD (table 3), consistent with their lower
lung function (table 2).
Factors associated with physician-assessed severity
In multivariable ordinal regression analysis among all patients with asthma or COPD, several clinical and
spirometric factors were associated with greater physician-assessed severity (supplementary figure S4a).
Notably, current smoking was associated with a lower severity classification than never/former smoking;
TABLE 3 Medications and biomarkers in the NOVELTY population, by physician-assigned diagnosis and severity#
Physician-assigned asthma Physician-assigned asthma+COPD Physician-assigned COPD
Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe
Subjects N¶ 2175 2108 1652 243 626 523 1125 1206 1574
Respiratory medications+
N with medication data 2059 2082 1622 236 614 519 935 1149 1547
N with ICS dose data 1820 1882 1499 219 563 477 880 1082 1450
No ICS§ 390 (18.9) 134 (6.4) 103 (6.4) 65 (27.5) 98 (16.0) 55 (10.6) 543 (58.1) 587 (51.1) 469 (30.3)
Short-acting BD, no ICS§ 329 (16.0) 109 (5.2) 50 (3.1) 45 (19.1) 72 (11.7) 31 (6.0) 280 (29.9) 296 (25.8) 263 (17.0)
LABA and/or LAMA, no
ICS§
18 (0.9) 13 (0.6) 18 (1.1) 32 (13.6) 66 (10.7) 39 (7.5) 391 (41.8) 497 (43.3) 388 (25.1)
Low-dose ICS 229 (12.6) 60 (3.2) 12 (0.8) 6 (2.7) 7 (1.2) 0 (0.0) 20 (2.3) 5 (0.5) 6 (0.4)
Low-dose ICS+LABA 410 (22.5) 444 (23.6) 106 (7.1) 32 (14.6) 58 (10.3) 20 (4.2) 75 (8.5) 61 (5.6) 38 (2.6)
Med/high-dose ICS+LABA 466 (25.6) 855 (45.4) 443 (29.6) 44 (20.1) 107 (19.0) 66 (13.8) 76 (8.6) 77 (7.1) 112 (7.7)
ICS+LABA+LAMAƒ 61 (3.0) 158 (7.6) 270 (16.6) 56 (23.7) 266 (43.3) 260 (50.1) 140 (15.0) 346 (30.1) 766 (49.5)
Maintenance OCS 43 (2.1) 80 (3.8) 217 (13.4) 3 (1.3) 22 (3.6) 58 (11.2) 10 (1.1) 17 (1.5) 70 (4.5)
Biologic therapy 14 (0.7) 61 (2.9) 491 (30.3) 2 (0.8) 7 (1.1) 49 (9.4) 0 (0.0) 1 (0.1) 2 (0.1)
Leukotriene modifier 415 (20.2) 617 (29.6) 638 (39.3) 23 (9.7) 112 (18.2) 157 (30.3) 26 (2.8) 33 (2.9) 53 (3.4)
Blood eosinophil count
109·μL−1
0.16±2.00 0.17±2.10 0.18±2.19 0.15±1.89 0.16±1.97 0.16±2.12 0.14±1.88 0.15±1.90 0.15±1.89
N without OCS, anti-IL-4/
4R or anti-IL5/5R




0.16±1.99 0.17±2.09 0.19±2.07 0.16±1.87 0.16±1.95 0.17±2.14 0.14±1.9 0.15±1.91 0.15±1.89
Blood eosinophil
proportion (% of total
leukocytes)




2.34±1.94 2.45±2.02 2.35±2.06 2.30±1.86 2.18±1.97 2.05±2.15 1.85±1.86 1.88±1.86 1.69±1.86
Blood neutrophil count
109·μL−1
3.84±1.41 4.00±1.43 4.5±1.50 4.27±1.45 4.52±1.46 4.7±1.45 4.26±1.39 4.42±1.42 4.89±1.44
Blood neutrophil
proportion (% of total
leukocytes)
55.16±1.19 56.06±1.17 51.14±1.17 61.39±1.17 58.46±1.16 56.76±1.18 51.28±1.15 53.43±1.19 52.56±1.17







































Data are presented as n (%) or geometric mean±geometric SD, unless otherwise indicated. For percentages, the denominator is given when different
from the total number of patients (N with data, excluding “unknown”). COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid;
BD: bronchodilator; LABA: long-acting β2-agonist; LAMA: long-acting muscarinic antagonist; OCS: oral corticosteroid; IL-4/4R: interleukin-4 or
interleukin-4 receptor; IL-5/5R: interleukin-5 or interleukin-5 receptor; IQR: interquartile range; FENO: fractional exhaled nitric oxide.
#: recruitment
was stratified by diagnosis/severity with the aim of achieving similar numbers of patients in each group; for patients with asthma+COPD, the
severity category is the worse of the two physician-assigned severity classifications, and patients with COPD classified as “very severe” were
included in the “severe” group; ¶: ∼50% of patients had biomarker data; +: medication categories are defined in supplementary table S2 and ICS
dose was classified according to Global Initiative for Asthma 2019 definition [37]; §: “no ICS” was defined as neither maintenance nor reliever ICS;
ƒ: without maintenance OCS or biologic therapy.
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obesity was also independently associated with lower severity. Supplementary figure S4 also shows
significant factors for asthma and COPD separately. Results of the univariate analysis are shown in
supplementary figure S5.
Discussion
The results of this cross-sectional analysis of patients with diagnoses of asthma and/or COPD, recruited from
primary care, specialist care and other settings, demonstrate marked heterogeneity within, and overlap
between, each diagnostic label and physician-assessed severity category. The features typically used to define
asthma and COPD in clinical trials and mechanistic studies were found across all subgroups of patients. This
indicates that the historical labels of “asthma” and “COPD” and the severity classifications used in clinical
practice do not identify clinically distinct populations. Furthermore, the findings confirm that there is a
clinical and healthcare utilisation burden of symptoms and exacerbations, even among patients considered by
their physician to have mild disease. These findings have important implications for asthma and COPD
management, because they demonstrate that patients with specific risks and treatment needs are not clearly
distinguishable from other groups in clinical practice using conventional criteria. NOVELTY thus fills a
conspicuous gap in evidence about asthma and/or COPD in broad populations, a gap that, to date, has
limited progress in understanding the underlying mechanisms and progression of new therapies. Our findings
emphasise the need for a deeper understanding of phenotypes and endotypes of asthma and/or COPD, and
challenge the specificity and utility of conventional classifications of “asthma” and “COPD”.
Most previous studies describing characteristics of patients with asthma or COPD (including large cohort
studies such as SPIROMICS and U-BIOPRED) have focused on selected populations with either
diagnosis, based on conventional criteria, from a particular care setting or geographic region, or focused on
severe disease [9–11]. By contrast, NOVELTY enrolled patients with physician diagnoses of asthma and/or
COPD, with very few inclusion and exclusion criteria, from a variety of clinical and healthcare settings
globally, allowing future investigation of regional differences in the features and management of asthma
and/or COPD. Almost half were recruited from primary care, where most patients with asthma or COPD
are treated. This supports the generalisability of present and future NOVELTY findings to real-world
clinical practice.
To fulfil the aims of NOVELTY, patients were recruited based on physician-assigned diagnosis, with no
diagnostic criteria specified. At baseline, fewer than two thirds of patients with COPD had persistent
airflow limitation (post-bronchodilator FEV1/FVC <LLN), which is consistent with other recent findings
[18, 19]. While variability in post-bronchodilator FEV1/FVC over time [20, 21] may have contributed,
spirometry is often not used in clinical practice; however, the concept of defining COPD, a complex and
often systemic disease, by a single number should be challenged [20]. Furthermore, almost one quarter of
patients labelled as having asthma and 62% of those labelled as having asthma+COPD demonstrated
persistent airflow limitation, and significant bronchodilator responsiveness was found in 15.9% of patients
labelled as having asthma and 13.1% of patients labelled as having COPD, slightly lower than in other
large, global population studies [22]. Asthma guidelines emphasise the importance of confirming the
diagnosis before treatment is started or the effects of remodelling and ageing are superimposed, and that a
single test may not be sufficient [2], yet bronchodilator responsiveness continues to be required for
eligibility for clinical asthma studies.
In this baseline analysis, clinical, physiological and biomarker characteristics overlapped extensively between
patients with physician-assigned diagnoses of asthma, asthma+COPD and COPD. Features such as allergic
rhinitis and nasal polyposis, commonly associated with asthma [23], and smoking and emphysema, commonly
associated with COPD [24], were present across all diagnoses. Blood eosinophil counts were similar across
diagnosis and severity groups, but blood neutrophil counts were higher with higher physician-assessed
severity, which is consistent with recent observations that higher blood neutrophil counts in COPD are
associated with lower lung function [25], and in asthma with risk of exacerbations requiring OCS [26]. These
findings support the emerging view that conventional diagnostic categories in asthma and COPD are
oversimplified and generalise complex and heterogeneous conditions [7]. The use of these diagnostic labels in
study design reduces opportunities to explore important underlying mechanistic pathways and more targeted
treatment options across the spectrum of obstructive lung disease. NOVELTY aims to address this problem
with its broad, unrestricted patient population, long-term data collection and analysis of known and emerging
biomarkers [12]. Future analyses of NOVELTY data will aim to find new ways of classifying patients
according to phenotypes and endotypes rather than by diagnostic label alone, to support the development of
precision medicine and point-of-care biomarkers for obstructive lung disease [8, 27, 28].
https://doi.org/10.1183/13993003.03927-2020 12
EUROPEAN RESPIRATORY JOURNAL ORIGINAL RESEARCH ARTICLE | H.K. REDDEL ET AL.
In the meantime, though, the labels of asthma and asthma+COPD remain clinically important because,
while the specific mechanisms are yet to be identified, patients with these diagnoses have a significantly
increased risk of death or hospitalisation if treated with LABA alone (without ICS) [29–31], compared
with patients with a diagnosis only of COPD [29, 31]. In the present analysis, 10.9% of patients with
asthma and 15.9% with asthma+COPD were not receiving any ICS. There was also evidence suggestive of
both over- and under-treatment, relative to severity, across all diagnostic groups.
To date, few data are available to guide treatment in patients with features of both asthma and COPD [32]
(often given interim descriptive labels of asthma–COPD overlap or asthma+COPD [2]). Most such
NOVELTY patients had received the asthma diagnosis first, suggesting that the COPD diagnosis was added
when symptoms and/or airflow limitation became persistent. Among patients with asthma+COPD,
physiological and clinical features lay between those of patients with asthma only and COPD only, but
symptoms, HRQoL and non-respiratory comorbidities were more similar to COPD. However, as in previous
reports [33], there was a greater burden of exacerbations with asthma+COPD than with either diagnosis alone.
Comparison of baseline characteristics by physician-assessed severity showed clear gradations by severity
in symptoms, HRQoL, lung function and exacerbations. Severity category was also associated with
diagnosis-aligned features that are known to be associated with more troublesome disease, such as allergic/
non-allergic upper airway disease (for asthma) and emphysema (for COPD). However, some patients with
physician-assessed mild asthma had features associated with poor outcomes (e.g. low lung function and
exacerbations). This suggests that the criteria used by physicians to assess severity and thus make treatment
decisions do not adequately identify patients at risk of adverse outcomes, including death [7]. BLOOM and
colleagues [34, 35] have reported that some patients with mild asthma (defined by treatment level)
experience severe exacerbations, and a recent meta-analysis [36] identified a wide range of exacerbation
rates in mild asthma.
The strengths of NOVELTY are that it is a large, global, longitudinal observational study of patients
recruited from clinical practice, almost half from primary care, without the limitations of current severity
classifications or the criteria that are recommended in clinical guidelines for initial diagnosis at the time of
first presentation, which are often required by regulators for pharmacotherapy studies regardless of disease
duration. Inclusion of current smokers with asthma and never-smokers with COPD enables a broader
investigation of mechanisms and perspective on comorbidity patterns. The use of “diagnosis-agnostic”
tools for symptoms and health status (mMRC, SGRQ and CAAT) ensures that findings can be reported
across the entire population, regardless of diagnostic label. These features increase the generalisability of
the present and future findings to real-world clinical practice across the spectrum of asthma and/or COPD.
Limitations include that the NOVELTY population is not a random sample (recruitment was stratified in
each country/region with target numbers by diagnosis/severity to ensure sufficient subgroup samples), so
whole-population results cannot be used to infer prevalence. Some baseline variables, such as
exacerbations in the past 12 months, were subject to recall bias; future analysis of the prospective
longitudinal follow-up data will provide more accurate data. Finally, because NOVELTY is an
observational study of patients in a real-world setting, these findings represent the characteristics of
patients already on treatment, which may differ from those present at the time of diagnosis.
Conclusions
This analysis of baseline characteristics in the NOVELTY population demonstrates marked heterogeneity
within and considerable overlap between physician-assigned diagnoses of asthma and/or COPD, including
by physician-assessed severity. These findings indicate that the diagnostic and severity classifications used
by physicians in real-world clinical practice poorly differentiate between clinical phenotypes, potentially
leading to unsuitable or unsafe treatment decisions. This emphasises the importance of identifying and
validating biomarkers to identify target populations (particularly those characterised by different
trajectories over time) from which molecular endotypes of asthma and/or COPD can be elucidated, and
more precise clinical classification and treatment decisions can be made.
Acknowledgements: The authors would like to thank the patients who participated in this study and the NOVELTY
study investigators (listed below). The authors also thank Richard J. Martin (National Jewish Health and the
University of Colorado, Denver, CO, USA) for his contribution to the NOVELTY study design and interpretation of
data as a member of the NOVELTY Scientific Committee, and Laura Belton and Crina Samarghitean (AstraZeneca)
for their critical review of the manuscript. Medical writing support, under the direction of the authors, was
provided by Nina Divorty, PhD, CMC Connect, McCann Health Medical Communications, and was funded by
https://doi.org/10.1183/13993003.03927-2020 13
EUROPEAN RESPIRATORY JOURNAL ORIGINAL RESEARCH ARTICLE | H.K. REDDEL ET AL.
AstraZeneca, Cambridge, UK, in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med
2015; 163: 461–464). J. Vestbo is supported by the NIHR Manchester Biomedical Research Centre and the NIHR
Manchester Clinical Research Facility.
List of NOVELTY study investigators: Gabriel Benhabib, Xavier Bocca Ruiz, Ricardo del Olmo, Raul Eduardo Lisanti,
Gustavo Marino, Walter Mattarucco, Juan Nogueira, Maria Parody, Pablo Pascale, Pablo Rodriguez, Damian Silva,
Graciela Svetliza, Carlos F. Victorio, Roxana Willigs Rolon, Anahi Yañez (Argentina); Stuart Baines, Simon Bowler,
Peter Bremner, Sheetal Bull, Patrick Carroll, Mariam Chaalan, Claude Farah, Gary Hammerschlag, Kerry Hancock,
Zinta Harrington, Gregory Katsoulotos, Joshua Kim, David Langton, Donald Lee, Matthew Peters, Lakshman
Prassad, Helen Reddel, Dimitar Sajkov, Francis Santiago, Frederick Graham Simpson, Sze Tai, Paul Thomas, Peter
Wark (Australia); José Eduardo Delfini Cançado, Thúlio Cunha, Marina Lima, Alexandre Pinto Cardoso, Marcelo
Rabahi (Brazil); Syed Anees, John Bertley, Alan Bell, Amarjit Cheema, Guy Chouinard, Michael Csanadi, Anil Dhar,
Ripple Dhillon, J. Mark FitzGerald, David Kanawaty, Allan Kelly, William Killorn, Daniel Landry, Robert Luton,
Piushkumar Mandhane, Andrew McIvor, Bonavuth Pek, Robert Petrella, Daniel Stollery (Canada); Meihua Chen, Yan
Chen, Wei Gu, Kim Ming Christopher Hui, Manxiang Li, Shiyue Li, Ma Lijun, Guangyue Qin, Weidong Song, Wei Tan,
Yijun Tang, Chen Wang, Tan Wang, Fuqiang Wen, Feng Wu, PingChao Xiang, Zuke Xiao, Shengdao Xiong, Jinghua
Yang, Jingping Yang, Caiqing Zhang, Min Zhang, Ping Zhang, Wei Zhang, Xiaohe Zheng, Dan Zhu (China; data for
patients from China were excluded from the present analyses due to a change in regulations about data transfer in
May 2019); Fabio Bolivar Grimaldos, Alejandra Cañas Arboleda, Carlos Matiz Bueno, Dora Molina de Salazar
(Colombia); Elisabeth Bendstrup, Ole Hilberg, Carsten Kjellerup, Ulla Weinreich (Denmark); Philippe Bonniaud,
Olivier Brun, Pierre-Régis Burgel, Christos Chouaid, Francis Couturaud, Jacques de Blic, Didier Debieuvre,
Dominique Delsart, Axelle Demaegdt, Pascal Demoly, Antoine Deschildre, Gilles Devouassoux, Carole Egron, Lionel
Falchero, François Goupil, Romain Kessler, Pascal Le Roux, Pascal Mabire, Guillaume Mahay, Stéphanie Martinez,
Boris Melloni, Laurent Moreau, Chantal Raherison, Emilie Riviere, Pauline Roux-Claudé, Michel Soulier, Guillaume
Vignal, Azzedine Yaici (France); Sven Philip Aries, Robert Bals, Ekkehard Beck, Andreas Deimling, Jan Feimer, Vera
Grimm-Sachs, Gesine Groth, Felix Herth, Gerhard Hoheisel, Frank Kanniess, Thomas Lienert, Silke Mronga, Jörg
Reinhardt, Christian Schlenska, Christoph Stolpe, Ishak Teber, Hartmut Timmermann, Thomas Ulrich, Peter Velling,
Sabina Wehgartner-Winkler, Juergen Welling, Ernst-Joachim Winkelmann (Germany); Carlo Barbetta, Fulvio Braido,
Vittorio Cardaci, Enrico Maria Clini, Maria Teresa Costantino, Giuseppina Cuttitta, Mario di Gioacchino, Alessandro
Fois, Maria Pia Foschino-Barbaro, Enrico Gammeri, Riccardo Inchingolo, Federico Lavorini, Antonio Molino,
Eleonora Nucera, Alberto Papi, Vincenzo Patella, Alberto Pesci, Fabio Ricciardolo, Paola Rogliani, Riccardo Sarzani,
Carlo Vancheri, Rigoletta Vincenti (Italy); Takeo Endo, Masaki Fujita, Yu Hara, Takahiko Horiguchi, Keita Hosoi,
Yumiko Ide, Minehiko Inomata, Hiromasa Inoue, Koji Inoue, Sumito Inoue, Motokazu Kato, Masayuki Kawasaki,
Tomotaka Kawayama, Toshiyuki Kita, Kanako Kobayashi, Hiroshi Koto, Koichi Nishi, Junpei Saito, Yasuo Shimizu,
Toshihiro Shirai, Naruhiko Sugihara, Ken-ichi Takahashi, Hiroyuki Tashimo, Keisuke Tomii, Takashi Yamada, Masaru
Yanai (Japan); Ruth Cerino Javier, Alfredo Domínguez Peregrina, Marco Fernández Corzo, Efraín Montano Gonzalez,
Alejandra Ramírez-Venegas, Adrian Rendon (Mexico); Willem Boersma, R.S. Djamin, Michiel Eijsvogel, Frits Franssen,
Martijn Goosens, Lidwien Graat-Verboom, Johannes in ’t Veen, Rob Janssen, Kim Kuppens, Maarten van den Berge,
Mario van de Ven (The Netherlands); Ole Petter Brunstad, Gunnar Einvik, Kristian Jong Høines, Alamdar Khusrawi,
Torbjorn Oien (Norway); Yoon-Seok Chang, Young Joo Cho, Yong Il Hwang, Woo Jin Kim, Young-Il Koh, Byung-Jae
Lee, Kwan-Ho Lee, Sang-Pyo Lee, Yong Chul Lee, Seong Yong Lim, Kyung Hun Min, Yeon-Mok Oh, Choon-Sik Park,
Hae-Sim Park, Heung-Woo Park, Chin Kook Rhee, Ho Joo Yoon, Hyoung-Kyu Yoon (South Korea); Alvar Agusti
García-Navarro, Rubén Andújar, Laura Anoro, María Buendía García, Paloma Campo Mozo, Sergio Campos,
Francisco Casas Maldonado, Manuel Castilla Martínez, Carolina Cisneros Serrano, Lorena Comeche Casanova,
Dolores Corbacho, Felix Del Campo Matías, Jose Echave-Sustaeta, Gloria Francisco Corral, Pedro Gamboa Setién,
Marta García Clemente, Ignacio García Núñez, Jose García Robaina, Mercedes García Salmones, Jose Maria Marín
Trigo, Marta Nuñez Fernandez, Sara Nuñez Palomo, José Olaguibel Rivera, Luis Pérez de Llano, Ana Pueyo Bastida,
Ana Rañó, José Rodríguez González-Moro, Albert Roger Reig, José Velasco Garrido (Spain); Dan Curiac, Christer
Janson, Cornelia Lif-Tiberg, Anders Luts, Lennart Råhlen, Stefan Rustscheff (Sweden); Frances Adams, Drew
Bradman, Emma Broughton, John Cosgrove, Patrick Flood-Page, Liz Fuller, Timothy Harrison, David Hartley, Keith
Hattotuwa, Gareth Jones, Keir Lewis, Lorcan McGarvey, Alyn Morice, Preeti Pandya, Manish Patel, Kay Roy,
Ramamurthy Sathyamurthy, Swaminathan Thiagarajan, Alice Turner, Jørgen Vestbo, Wisia Wedzicha, Tom
Wilkinson, Pete Wilson (UK); Lo’Ay Al-Asadi, James Anholm, Frank Averill, Sandeep Bansal, Alan Baptist, Colin
Campbell, Michael A. Campos, Bradley Chipps, Gretchen Crook, Samuel DeLeon, Alain Eid, Ellen Epstein, Stephen
Fritz, Hoadley Harris, Mitzie Hewitt, Fernando Holguin, Golda Hudes, Richard Jackson, Alan Kaufman, David
Kaufman, Ari Klapholz, Harshavardhan Krishna, Daria Lee, Robert Lin, Diego Maselli-Caceres, Vinay Mehta, James
N. Moy, Ugo Nwokoro, Purvi Parikh. Sudhir Parikh, Frank Perrino, James Ruhlmann, Catherine Sassoon, Russell A.
Settipane, Daniel Sousa, Peruvemba Sriram, Richard Wachs (USA).
ClinicalTrials.gov identifier: NCT02760329. Data underlying the findings described in this manuscript may be
obtained in accordance with AstraZeneca’s data-sharing policy described at https://astrazenecagrouptrials.
https://doi.org/10.1183/13993003.03927-2020 14
EUROPEAN RESPIRATORY JOURNAL ORIGINAL RESEARCH ARTICLE | H.K. REDDEL ET AL.
pharmacm.com/ST/Submission/Disclosure. The study protocol is available at https://astrazenecagrouptrials.
pharmacm.com.
Author contributions: All authors, including those who were AstraZeneca employees, contributed to the study
design, analysis and/or interpretation of data and critical review of the manuscript. All authors had full access to,
and contributed to the interpretation of, all data reported herein. The corresponding author had final
responsibility for the decision to submit for publication.
Conflict of interest: H.K. Reddel reports grants, personal fees and non-financial support from AstraZeneca, during
the conduct of the study; grants and personal fees for data monitoring committee work, advisory board work and
providing independent medical education from AstraZeneca and GlaxoSmithKline, personal fees for data
monitoring committee work from Merck, personal fees for data monitoring committee work, advisory board work
and grant for registry from Novartis, personal fees for providing independent medical education from Teva,
personal fees for advisory board work and providing independent medical education from Boehringer Ingelheim,
and personal fees for advisory board work from Sanofi Genzyme and Chiesi, outside the submitted work; and is
Chair of the GINA Scientific Committee and a member of the GINA Board. J. Vestbo reports personal fees for
steering committee work from AstraZeneca, during the conduct of the study; and personal fees for consultancy
and lectures from GlaxoSmithKline, Chiesi Pharmaceuticals, Novartis and AstraZeneca, and grants and personal
fees for consultancy and lectures from Boehringer Ingelheim, outside the submitted work. A. Agusti reports
personal fees for scientific committee work from AstraZeneca, during the conduct of the study; and grants and
personal fees for lectures and advisory board work from GlaxoSmithKline and Menarini, and personal fees for
lectures and advisory board work from Chiesi, outside the submitted work. G.P. Anderson reports personal fees for
consultancy and share options from Pieris Pharmaceuticals, ENA Therapeutics and ENA Respiratory, personal fees
for scientific committee work from AstraZeneca, and personal fees for lectures from GlaxoSmithKline, AstraZeneca,
Menarini and Novartis, outside the submitted work; and has US Patent 7,455,836 licensed to MorphoSys,
sublicensed to GlaxoSmithKline. A.T. Bansal has nothing to disclose. R. Beasley reports personal fees for steering
committee work from AstraZeneca, during the conduct of the study; and grants and personal fees from
AstraZeneca and GlaxoSmithKline, personal fees from Avillion and Theravance, and grants from Genentech,
outside the submitted work. E.H. Bel reports grants and personal fees from AstraZeneca, GlaxoSmithKline,
Novartis and Teva, and personal fees from Sanofi/Regeneron, Sterna and Chiesi, outside the submitted work.
C. Janson reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and
Teva, outside the submitted work. B. Make reports grants, non-financial support and other (advisory board and
presentations) from AstraZeneca, grants, non-financial support and other from GlaxoSmithKline, non-financial
support for data monitoring committee work from Spiration, grants, non-financial support and other (advisory
board) from Sunovion, other (CME activity) from Mt. Sinai, Web MD, National Jewish Health, Novartis, American
College of Chest Physicians, Projects in Knowledge, Hybrid Communications, Medscape, Ultimate Medical
Academy, Eastern Pulmonary Society, Catamount Medical, Eastern VA Medical Center, Academy Continued Health
Care Learning and Wolters Kluwer Health, grants from Pearl Research and NHLBI, other (advisory board) from
Verona, Boehringer Ingelheim, Theravance and Science 24/7, non-financial support and other (advisory board)
from Circassia and Phillips, personal fees and non-financial support for consultancy from Third Pole, non-financial
support and other (data monitoring committee) from Shire, and personal fees for data monitoring committee
work from Takeda, outside the submitted work. I.D. Pavord reports personal fees for lectures, advisory board
work, meeting attendance and organising educational events from AstraZeneca, personal fees for lectures,
advisory board work and meeting attendance from Boehringer Ingelheim and GlaxoSmithKline, personal fees for
lectures from Aerocrine and Chiesi, personal fees for lectures and advisory board work from Almirall and Novartis,
personal fees for advisory board work from Genentech, Regeneron, Sanofi, Circassia and Knopp, personal fees for
lectures, meeting attendance and organising educational events from Teva, and grants from NIHR, outside the
submitted work. D. Price reports study funding from AstraZeneca, during the conduct of the study; personal fees
for advisory board work and consultancy from Amgen, grants and personal fees for advisory board work, lectures,
consultancy and travel/accommodation/meeting expenses from AstraZeneca and Boehringer Ingelheim, grants and
personal fees for advisory board work, lectures and consultancy from Chiesi, Mylan and Teva, grants and personal
fees for advisory board work from Circassia, personal fees for lectures from Cipla and Kyorin, personal fees for
consultancy and lectures from GlaxoSmithKline, grants and personal fees for advisory board work, lectures,
consultancy, travel/accommodation/meeting expenses and educational activities from Mundipharma and Novartis,
grants and personal fees for consultancy from Pfizer and Theravance, grants and personal fees for advisory board
work and lectures from Regeneron Pharmaceuticals and Sanofi Genzyme, grants from Respiratory Effectiveness
Group and UK National Health Service, personal fees for advisory board work and travel/accommodation/meeting
expenses from ThermoFisher, non-financial support for grant committee reviewing from Efficacy and Evaluation
Mechanism Programme and Health Technology Assessment, outside the submitted work; has stock/stock options
from AKL Research and Development Ltd which produces phytopharmaceuticals; and is part owner of the social
enterprise Optimum Patient Care Ltd (Australia and UK) and of the Observational and Pragmatic Research Institute
https://doi.org/10.1183/13993003.03927-2020 15
EUROPEAN RESPIRATORY JOURNAL ORIGINAL RESEARCH ARTICLE | H.K. REDDEL ET AL.
Pte Ltd (Singapore). E. Rapsomaniki is an employee of AstraZeneca (UK). N. Karlsson is an employee of
AstraZeneca. D.K. Finch was an employee of AstraZeneca at the time of authorship. J. Nuevo is an employee of
AstraZeneca. A. de Giorgio-Miller has nothing to disclose. M. Alacqua has nothing to disclose. R. Hughes reports
personal fees from GlaxoSmithKline, Novartis, Boehringer Ingelheim and AstraZeneca, outside the submitted work;
and is an employee of AstraZeneca. H. Müllerová is an employee of AstraZeneca. M. Gerhardsson de Verdier is an
employee of AstraZeneca.
Support statement: The NOVELTY study is funded by AstraZeneca.
References
1 GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national
incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and
territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392:
1789–1858.
2 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2021 Update).
www.ginasthma.org/reports/ Date last updated: 2020. Date last accessed: July 1, 2021.
3 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and
Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). www.goldcopd.org/2021-gold-reports/
Last updated: 2021. Date last accessed: July 1, 2021.
4 Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or
stereotype. Eur Respir J 2018; 52: 1801444.
5 Halpin DMG, Kerkhof M, Soriano JB, et al. Eligibility of real-life patients with COPD for inclusion in trials of
inhaled long-acting bronchodilator therapy. Respir Res 2016; 17: 120.
6 Vestbo J, Janson C, Nuevo J, et al. Observational studies assessing the pharmacological treatment of
obstructive lung disease: strengths, challenges and considerations for study design. ERJ Open Res 2020; 6:
00044–2020.
7 Pavord ID, Beasley R, Agustí A, et al. After asthma: redefining airways diseases. Lancet 2018; 391: 350–400.
8 Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex,
heterogeneous disease. Lancet 2008; 372: 1107–1119.
9 SPIROMICS. Participating Institutions. www2.cscc.unc.edu/spiromics/ParticipatingInstitutions Date last
accessed: March 2, 2020.
10 U-BIOPRED. Who Is Involved? www.europeanlung.org/en/projects-and-research/projects/u-biopred/
who-is-involved/ Date last accessed: March 2, 2020.
11 Lifelines. Lifelines: A Unique Biobank and Databank. https://lifelines.nl/lifelines-research/general Date last
accessed: March 2, 2020.
12 Reddel HK, Gerhardsson de Verdier M, Agustí A, et al. Prospective observational study in patients with
obstructive lung disease: NOVELTY design. ERJ Open Res 2019; 5: 00036–2018.
13 Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age
range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324–1343.
14 Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society
statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical
practice. Am J Respir Crit Care Med 2009; 180: 59–99.
15 Fletcher CM. Standardized questionaries on respiratory symptoms: a statement prepared for, and approved
by, the Medical Research Council’s Committee on the Aetiology of Chronic Bronchitis. BMJ 1960; 2: 1665.
16 Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow
limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321–1327.
17 Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur
Respir J 2009; 34: 648–654.
18 Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2018; 198: 1130–1139.
19 Sator L, Horner A, Studnicka M, et al. Overdiagnosis of COPD in subjects with unobstructed spirometry: a
BOLD analysis. Chest 2019; 156: 277–288.
20 Schermer TR, Robberts B, Crockett AJ, et al. Should the diagnosis of COPD be based on a single spirometry
test? NPJ Prim Care Respir Med 2016; 26: 16059.
21 Aaron SD, Tan WC, Bourbeau J, et al. Diagnostic instability and reversals of chronic obstructive pulmonary disease
diagnosis in individuals with mild to moderate airflow obstruction. Am J Respir Crit Care Med 2017; 196: 306–314.
22 Janson C, Malinovschi A, Amaral AFS, et al. Bronchodilator reversibility in asthma and COPD: findings from
three large population studies. Eur Respir J 2019; 54: 1900561.
23 Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED
adult severe asthma cohort. Eur Respir J 2015; 46: 1308–1321.
https://doi.org/10.1183/13993003.03927-2020 16
EUROPEAN RESPIRATORY JOURNAL ORIGINAL RESEARCH ARTICLE | H.K. REDDEL ET AL.
24 Agustí A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir
Res 2010; 11: 122.
25 Halper-Stromberg E, Yun JH, Parker MM, et al. Systemic markers of adaptive and innate immunity are
associated with chronic obstructive pulmonary disease severity and spirometric disease progression. Am J
Respir Cell Mol Biol 2018; 58: 500–509.
26 Vedel-Krogh S, Fallgaard Nielsen S, Lange P, et al. Association of blood eosinophil and blood neutrophil
counts with asthma exacerbations in the Copenhagen General Population Study. Clin Chem 2017; 63:
823–832.
27 Agustí A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur
Respir J 2016; 47: 410–419.
28 Agustí A, Bafadhel M, Beasley R, et al. Precision medicine in airway diseases: moving to clinical practice. Eur
Respir J 2017; 50: 1701655.
29 Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting β-agonists and inhaled corticosteroids
compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease.
JAMA 2014; 312: 1114–1121.
30 McMahon AW, Levenson MS, McEvoy BW, et al. Age and risks of FDA-approved long-acting β₂-adrenergic
receptor agonists. Pediatrics 2011; 128: e1147–e1154.
31 Kendzerska T, Aaron SD, To T, et al. Effectiveness and safety of inhaled corticosteroids in older individuals
with chronic obstructive pulmonary disease and/or asthma. A population study. Ann Am Thorac Soc 2019; 16:
1252–1262.
32 Reddel HK. Treatment of overlapping asthma-chronic obstructive pulmonary disease: can guidelines
contribute in an evidence-free zone? J Allergy Clin Immunol 2015; 136: 546–552.
33 Nielsen M, Bårnes CB, Ulrik CS. Clinical characteristics of the asthma–COPD overlap syndrome – a systematic
review. Int J Chron Obstruct Pulmon Dis 2015; 10: 1443–1454.
34 Bloom CI, Nissen F, Douglas IJ, et al. Exacerbation risk and characterisation of the UK’s asthma population
from infants to old age. Thorax 2018; 73: 313–320.
35 Bloom CI, Palmer T, Feary J, et al. Exacerbation patterns in adults with asthma in England. A
population-based study. Am J Respir Crit Care Med 2019; 199: 446–453.
36 FitzGerald JM, Barnes PJ, Chipps BE, et al. The burden of exacerbations in mild asthma: a systematic review.
ERJ Open Res 2020; 6: 00359–2019.
37 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2019 update).
https://ginasthma.org/archived-reports/ Date last accessed: March 2, 2020.
https://doi.org/10.1183/13993003.03927-2020 17
EUROPEAN RESPIRATORY JOURNAL ORIGINAL RESEARCH ARTICLE | H.K. REDDEL ET AL.
